Executive Search 🔁 Management Consulting: Biotech, Pharma, MedTech. Nonprofit. Drug Development. Rare & Common. Oncology. Neurology. RNA. Gene Tx. AI. DeSci.
Boston
Joined November 2011
- Tweets1.7K
- Following2.4K
- Followers634
- Likes3.8K
Jason Ford retweeted
Big day for @formationbio as we announce our $600M Drug Development Accelerator Fund. Unique among funds in that it's directed toward our core internal programs, complementing our balance sheet capital and deep drug development capabilities. Learn more below:
Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund.
@lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development.
As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients.
Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.
Jason Ford retweeted
Global Corporate Controller opportunity:
- Up to $250k + Bonus + LTI
- PE + MFG
- Cincy
Jason Ford retweeted
At the #NORDSummit, @CNBC's @BeckyQuick moderated a dialogue with the CEOs of NORD, @BioMarin, @JazzPharma, @OtsukaUS in which she challenged each of them to state their "wish list" for removing barriers to care for rare disease patients. Here were some of their answers:
• Cohesive patient data sets powered by foundations and advocacy groups
• More funding for organizations like #NORD to sustain that infrastructure
• Expanded newborn screening for rare, genetic conditions
• Improved medical awareness and education
• Diagnostic codes for more rare diseases
• More regulatory flexibility and fit-for-purpose standards for highly heterogenous diseases
• Consistency and predictability across #FDA review teams
• Exemptions from tariffs for orphan drug manufacturing
The overarching theme was that, to scale up #RareDisease research and treatment development, we need laws and regulatory policies that address the challenges patient communities and #biotech companies are facing, a #healthcare system with improved diagnostic capabilities, and well-funded patient organizations who can lead research efforts in their communities, in partnership with industry companies.
ALT Panelists on stage at the 2026 NORD Breakthrough Summit CEO Leadership Dialogue hosted by CNBC's Becky Quick, right.
Jason Ford retweeted
President and CEO Pam welcomed over 100 #NORD Member organization representatives to the 2026 #NORDSummit. Our Member organizations are the heart and souls of our movement. NORD's purpose is to bring the expertise necessary to advocate for the needs of each #RareDisease community.
ALT NORD CEO Pamela Gavin at the 2026 NORD Summit
We work at the Nexus of nonprofit impact and biotech innovation.
New search
CEO for the National MPS Society
They are a nonprofit foundation focused on #rare / #ultrarare diseases.
Organizational leadership, fundraising experience and a connection to Rare Diseases a plus
Nine biotech IPOs in Q3 2026-a five-year high, raised $2.4B, down from $3.8B in Q2. More listings don’t mean easy capital; XBI can’t capture the full funding picture, especially for early-stage firms.
XBI can rise while many biopharma companies remain under pressure. In September 2026, 86 U.S.-listed biopharma companies traded below cash, nearly 4× the pre-COVID average. XBI doesn’t show each company’s runway. #Biotech
XBI is a useful public-market barometer, not a full biotech health check. Up roughly 21% YTD as of Oct. 19, yet 11% below its August peak, it doesn’t capture private funding, runway, clinical progress or hiring. #Biotech
Jason Ford retweeted
The 2026 National Organization for Rare Disorders (#NORD) Rare Diseases and Orphan Products Breakthrough Summit® is taking place next week, Monday and Tuesday, in Washington, D.C. and virtually, and there's still time to reserve your place in the audience! Learn more and register at nordsummit.org.
#RareDisease #RareDiseases #Rare
ALT A person holding a laptop displaying a conference event. The screen shows a large audience in a dimly lit auditorium with a presentation on stage. The text reads "Access from Anywhere," featuring the NORD Breakthrough Summit logo. A circular text bubble states, "Join us October 25–27." The bottom message encourages joining conversations about what's next for the rare disease community.
One of the nuanced differences in Executive Search between nonprofits and industry.
Industry partners know when to use outside expertise, their question is which firm do I chose....
Nonprofit organizations often just do not believe in the value, and it can show by performance.
Q4 and early 2027 hiring continues year-round. Search firms bring comp insight, protect confidentiality, maintain momentum, and negotiate Q1 bonuses, buyouts & equity. Partners through the calendar, not just CVs. #Hiring
Current open non-profit opportunities:
VP of Corporate Development and Innovation (ALS)
CEO - rare and ultra rare diseases
COO - rare diseases, operational and finance
We are Denville Partners working at the nexus of nonprofit impact and biotech innovation.
Jason Ford retweeted
Rejuvenate Bio spun out of my lab at Harvard, and I co-founded it. One injection reverses cardiac disease in dogs, with three years of safety data and zero safety issues. They’ve raised $3.2M+ and 1,250+ investors are in, and Kingscrowd ranks the round #1 in the country. It closes soon: wefunder.com/rejuvenatebio
Jason Ford retweeted
Swallowing dysfunction in #DM1 can develop gradually. Signs may include difficulty chewing, coughing or choking when eating, food “sticking” in throat, longer meals, or weight loss. In some cases, there’s a risk of food or liquid entering the airway.
Recognizing symptoms early supports safer eating. #DM1SymptomSpotlight #MyotonicDystrophy
ALT DM1 Symptom Spotlight: Swallowing Dysfunction
When cash is tight, equity can support year-end hiring and retention, but only when benchmarked and explained transparently. It cannot replace clear strategy or competitive fundamentals. #ExecutiveSearch #LifeSciences
Senior hires shouldn’t absorb the cost of moving. Negotiate a make-whole package before the offer for forfeited Q1 bonuses or unvested equity, often 80–100% via a bridge bonus, replacement equity or salary adjustment.
Bonus season (Oct 1–Mar 31) can make senior hiring seasonal: candidates wait for Q1 2027 payouts, October/November slates look thin, and February/March gets crowded. Plan bonus, equity and search timing deliberately.
Jason Ford retweeted
SO excited about this news!
Congrats to the great team at @CityTx_ for this important milestone!
Go $CTY!
We’re excited to announce the pricing of our upsized initial public offering at $18.00 per share, for gross proceeds of approximately $200.0 million. City will trade on Nasdaq under the ticker $CTY.
Read more: investors.citytx.com/news-re…
As a search firm that focuses on rare disease drug development on both the industry in the nonprofit side, we look forward to supporting our partners as they drive their therapies into the hands of those who need them most.
